Zolmitriptan , ≥98%(HPLC) , 139264-17-8

Synonym(s):
(4S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone;(S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone;311C90

CAS NO.：139264-17-8

Empirical Formula: C16H21N3O2

Molecular Weight: 287.36

MDL number: MFCD00871503

EINECS: 629-919-0

PRODUCT Properties

• Melting point: 136-141°C
• alpha: D22 -5.79° (c = 0.5 in methanol)
• Boiling point: 563.3±38.0 °C(Predicted)
• Density: 1.217±0.06 g/cm3(Predicted)
• storage temp.: 15-25°C
• solubility: Soluble in DMSO at 5mg/ml
• pka: 9.64(at 25℃)
• form: powder
• color: white to beige
• optical activity: [α]/D -3 to -8°, c = 1 in methanol
• λmax: 225nm(lit.)
• Merck: 14,10189
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
• InChIKey: ULSDMUVEXKOYBU-ZDUSSCGKSA-N

Description and Uses

Zolmitriptan is a selective serotonin receptor agonist of the 1B and 1D subtypes. It is mainly used in the acute treatment of migraine attacks with or without aura and cluster headaches. Zolmitriptan takes effect through binding to human 5-HT1Band 5-HT1Dreceptors, leading to cranial blood vessel constriction and the release of sensory neuropeptides through nerve endings in the trigeminal system.

adrenergic agonist, nasal decongestant

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P264-P270-P301+P312+P330-P501
• Hazard Codes: Xi,Xn
• Risk Statements: 36/37/38-22
• Safety Statements: 26-36
• WGK Germany: 3
• RTECS: RQ2707000
• HS Code: 29349990
• Toxicity: women,TDLo,oral,6mg/kg/43W-I (6mg/kg),BEHAVIORAL: HEADACHE,Lancet. Vol. 353, Pg. 378, 1999.